A Plus Biotechnology Co., Ltd.
A Plus Biotechnology Co., Ltd. engages in the manufacturing and wholesale of orthopedic and other medical devices. The company offers products for chest, shoulder, spine, elbow, wrist and hand, pelvic and hip, knee, foot and ankle, osteotomy, pediatric and ESF, biologics. It also provides technical support services and labor services. A Plus Biotechnology Co., Ltd. is based in New Taipei City, Ta… Read more
A Plus Biotechnology Co., Ltd. (6918) - Total Assets
Latest total assets as of September 2025: NT$1.53 Billion TWD
Based on the latest financial reports, A Plus Biotechnology Co., Ltd. (6918) holds total assets worth NT$1.53 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
A Plus Biotechnology Co., Ltd. - Total Assets Trend (2021–2024)
This chart illustrates how A Plus Biotechnology Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
A Plus Biotechnology Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
A Plus Biotechnology Co., Ltd.'s total assets of NT$1.53 Billion consist of 76.2% current assets and 23.8% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 30.7% |
| Accounts Receivable | NT$178.97 Million | 15.2% |
| Inventory | NT$286.94 Million | 24.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how A Plus Biotechnology Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: A Plus Biotechnology Co., Ltd.'s current assets represent 76.2% of total assets in 2024, an increase from 63.1% in 2021.
- Cash Position: Cash and equivalents constituted 30.7% of total assets in 2024, up from 25.3% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 24.4% of total assets.
A Plus Biotechnology Co., Ltd. Competitors by Total Assets
Key competitors of A Plus Biotechnology Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
A Plus Biotechnology Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - A Plus Biotechnology Co., Ltd. generates 0.65x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, A Plus Biotechnology Co., Ltd. generates $ 12.83 in net profit.
A Plus Biotechnology Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.19 | 6.01 | 6.01 |
| Quick Ratio | 4.42 | 3.98 | 3.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$974.67 Million | NT$ 694.27 Million | NT$ 694.27 Million |
A Plus Biotechnology Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between A Plus Biotechnology Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.43 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 9.9% |
| Total Assets | NT$1.18 Billion |
| Market Capitalization | $61.12 Million USD |
Valuation Analysis
Below Book Valuation: The market values A Plus Biotechnology Co., Ltd.'s assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: A Plus Biotechnology Co., Ltd.'s assets grew by 9.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for A Plus Biotechnology Co., Ltd. (2021–2024)
The table below shows the annual total assets of A Plus Biotechnology Co., Ltd. from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.18 Billion | +9.89% |
| 2023-12-31 | NT$1.07 Billion | -8.79% |
| 2022-12-31 | NT$1.17 Billion | -2.60% |
| 2021-12-31 | NT$1.21 Billion | -- |